CRVO vs. BRVO: Key Differences in Retinal Vein Occlusion

Central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) are both caused by a blood clot in a retinal vein, but they differ in location, severity, and outlook. CRVO blocks the main vein draining the entire retina, while BRVO blocks one of its smaller tributaries, affecting only a portion of the retina. That anatomical distinction drives nearly every difference between the two conditions, from how much vision you lose at onset to how likely you are to develop sight-threatening complications afterward.

Where the Blockage Happens

Your retina has a single central retinal vein that carries blood out of the eye. Before reaching that central trunk, blood flows through smaller branch veins, each draining a sector of the retina. In BRVO, the clot forms at a point where a branch vein crosses under a retinal artery. The artery and vein share a common outer sheath at that crossing, and when the artery stiffens from atherosclerosis or high blood pressure, it compresses the vein underneath. That compression slows blood flow, encouraging a clot to form. Because only one branch is blocked, only the wedge of retina downstream from that branch is affected.

In CRVO, the blockage is in the central retinal vein itself, usually at or near the lamina cribrosa, the sieve-like structure where the optic nerve exits the eye. Since all retinal blood must funnel through this single vein, a clot here backs up blood across the entire retina. The result is far more widespread damage: hemorrhages, swelling, and oxygen deprivation that can extend from the optic disc to the periphery in all four quadrants.

Who Gets Each Type

Both CRVO and BRVO share the same broad set of systemic risk factors. High blood pressure, diabetes, high cholesterol, and cardiovascular disease all contribute by promoting changes in blood vessel walls, blood flow, and clotting tendency. A meta-analysis found that people diagnosed with CRVO were more likely to have metabolic syndrome and conditions like peripheral artery disease, deep venous thrombosis, and hypercoagulable states compared to the general population.¹ Systemic conditions like hypertension, diabetes, and dyslipidemia are recognized risk factors for retinal vein occlusion overall.²

The risk profiles diverge in interesting ways, though. BRVO is more tightly linked to hypertension and atherosclerotic vascular disease. One study found a significantly higher prevalence of arterial hypertension in BRVO than in CRVO, along with higher rates of peripheral vascular disease and cerebrovascular disease.³ That fits the mechanism: BRVO depends on artery-over-vein compression at crossing points, and stiffer, thicker arteries from hypertension make that compression worse.

CRVO, by contrast, has a stronger association with glaucoma and elevated eye pressure. A meta-analysis of the link between glaucoma and retinal vein occlusion found that glaucoma raised the odds of CRVO roughly sixfold, compared with about two-and-a-half-fold for BRVO.⁴ A Mendelian randomization study estimated that over 90% of the effect of high intraocular pressure on retinal vein occlusion risk was mediated through glaucoma, suggesting the structural changes glaucoma causes at the optic nerve head are what really squeeze the central vein.⁵ Population-based data shows that glaucoma patients develop retinal vein occlusion at roughly eight times the rate of the general population.⁶

When It Strikes Younger Adults

Most retinal vein occlusions happen in people over 50, driven by the usual cardiovascular risk factors. But when CRVO occurs in a younger person, the picture changes. A study of CRVO patients under 50 found that about one in nine had an underlying blood-clotting disorder within a year of diagnosis, regardless of whether they had traditional atherosclerotic risk factors. Testing rates were low, with only about 38% of young patients receiving a workup for clotting abnormalities.⁷ A systematic review reinforced the idea that a thorough hematological investigation is particularly worthwhile in young patients, people with a personal or family history of blood clots, and those with autoimmune conditions.⁸

BRVO in younger patients is rarer, and when it does occur, the same clotting-disorder workup can be warranted. But because BRVO is so mechanically tied to arteriovenous crossing-point compression, young BRVO patients are more likely to have an anatomical predisposition or early-onset hypertension than a primary clotting problem.

How Vision Loss Differs at Onset

The single biggest practical difference between CRVO and BRVO is how much vision you lose when it first happens. CRVO tends to hit harder. In a large natural-history study, nearly all eyes with ischemic CRVO (the more severe subtype) presented with vision of 20/200 or worse, compared to about one in five eyes with the milder, non-ischemic form.⁹ Visual field loss was also far more severe in ischemic CRVO, with over half of those eyes showing scotomas on testing versus only 5% of non-ischemic eyes.

BRVO typically causes a more localized visual disturbance. Because only one sector of the retina is affected, you might notice blurred or missing vision in one quadrant rather than a global dimming. If the blocked branch does not drain the macula (the central area responsible for sharp, detailed vision), you might barely notice anything at all. When the macula is involved, the main complaint is central blurriness from macular edema, the fluid buildup that is the most common cause of vision loss in both conditions.

Ischemic Versus Non-Ischemic CRVO

CRVO is further subdivided into ischemic and non-ischemic types, and this distinction matters enormously for prognosis. Non-ischemic CRVO (sometimes called “perfused” CRVO) accounts for roughly three-quarters of cases. The retinal blood supply is reduced but not devastated, hemorrhages tend to be milder, and the outlook is considerably better. Many non-ischemic eyes recover useful vision with treatment.

Ischemic CRVO is the more dangerous form. The retinal capillary bed is severely damaged, cutting off oxygen to large areas. On clinical exam and imaging, these eyes show dramatically more vein engorgement, capillary dropout, and fluorescein leakage.¹⁰ The oxygen-starved retina releases growth factors that can trigger dangerous new blood vessel formation. Vitreous levels of VEGF (the main growth signal) and inflammatory markers like interleukin-6 are markedly higher in ischemic CRVO eyes compared to non-ischemic ones, and both correlate with the severity of macular edema.¹¹

A non-ischemic CRVO can convert to the ischemic type over time, which is one reason regular follow-up is so important even when the initial presentation looks relatively mild. BRVO does not have this same binary classification, though it too can range from mild to severely ischemic depending on how much capillary territory is affected.

Complications and Neovascularization

The most feared complication of either type of vein occlusion is neovascularization, the growth of fragile, abnormal new blood vessels that can bleed or cause a devastating form of glaucoma. Where these abnormal vessels appear depends on which type of occlusion you have.

In CRVO, especially the ischemic form, neovascularization tends to appear on the iris and in the drainage angle at the front of the eye. This can obstruct fluid outflow and cause neovascular glaucoma, a painful and difficult-to-treat condition. The SCORE study, a large clinical trial, found that by 36 months the cumulative incidence of iris neovascularization or neovascular glaucoma was about 8.5% in CRVO eyes overall, rising sharply in eyes with extensive capillary nonperfusion.¹² In BRVO, the same complication was much rarer at about 2.4%. Instead, BRVO eyes that did develop neovascularization tended to grow abnormal vessels on the retinal surface or optic disc, which are more amenable to laser treatment.¹³

The amount of retinal nonperfusion is the strongest predictor of neovascularization in both types. In the SCORE data, CRVO eyes with large areas of capillary dropout had roughly four times the rate of neovascular glaucoma compared to eyes with less nonperfusion. In BRVO, the difference was even more dramatic for retinal neovascularization: about 15% in eyes with extensive nonperfusion versus about 2% without.¹⁴

How They Are Treated

Both CRVO and BRVO are primarily managed today with injections of anti-VEGF drugs into the eye. These medications block the growth factor that drives both macular edema and neovascularization. Treatment is effective for both conditions, but the trajectories differ.

BRVO eyes tend to respond more robustly and maintain their gains more easily. In one long-term observational study, BRVO eyes gained an average of about 14 letters on a standard vision chart (roughly three lines) with treatment extending to eight years, while CRVO eyes gained about 14 letters as well but started from a worse baseline.¹⁵ A large database analysis showed that at five years, BRVO eyes retained a gain of about 8 letters from baseline while CRVO eyes held about 5 letters.¹⁶ Another real-world study reported a similar pattern, with BRVO eyes showing about 8 letters of gain at five years and CRVO eyes about 7.¹⁷

Injection frequency is another practical concern. In the first year, both types require frequent injections, typically six to seven. Over time, the burden decreases. By year five, the median number of annual injections drops to around two or fewer for BRVO eyes, and CRVO eyes follow a similar trend, though with somewhat more variability.¹⁸ Across studies, eyes that received more injections tended to achieve better visual outcomes, which suggests undertreatment is a real problem in routine clinical practice.

Steroid implants injected into the eye are an alternative to anti-VEGF therapy, particularly for patients who cannot tolerate frequent injections. A dexamethasone implant lasts roughly four to six months per injection, reducing treatment visits. The trade-off is a higher risk of elevated eye pressure and cataracts compared to anti-VEGF drugs.¹⁹ For BRVO with significant retinal ischemia and neovascularization, laser photocoagulation to the affected sector can reduce the risk of vitreous hemorrhage, though one prospective trial found it did not improve visual acuity and actually worsened peripheral visual fields. The recommendation that emerged was to reserve laser for eyes where neovascularization has already developed rather than applying it preventively.²⁰

Modern Imaging and What It Reveals

Optical coherence tomography angiography (OCT-A) has transformed how doctors assess both types of vein occlusion without injecting dye. In CRVO, a key finding on OCT-A is enlargement of the foveal avascular zone, the tiny capillary-free area at the center of the macula. One study found that the size of this zone in the superficial retinal layer correlated with worse visual acuity, and disruption of a deeper retinal layer called the ellipsoid zone predicted both a larger avascular zone and poorer vision.²¹

In BRVO, OCT-A shows reduced vascular density in the affected sector compared to the healthy fellow eye, at both superficial and deep retinal layers. The foveal avascular zone in the deep network was significantly larger in BRVO eyes, and that enlargement also correlated with worse vision.²² These imaging findings help doctors gauge how much microvascular damage has occurred and anticipate the likely response to treatment.

Collateral Vessels and What They Signal

Over time, some eyes with vein occlusions develop collateral vessels, new pathways that reroute blood around the blockage. You might expect these to be a good sign, but the evidence points in the opposite direction. A study using widefield OCT-A found that more extensive collateral vessel development was correlated with worse final visual acuity and greater macular thickness in both CRVO and BRVO eyes.²³ The likely explanation is that extensive collateral formation is a marker of a more severe occlusion. The retina is working harder to compensate because the original blockage caused more damage, not because the collaterals are themselves harmful.

Quality of Life and the Burden of Each Type

Vision-related quality of life takes a measurable hit with any retinal vein occlusion, but CRVO patients report worse outcomes. A study using validated quality-of-life questionnaires found a statistically significant difference between the two groups, with CRVO patients scoring lower overall.²⁴ That aligns with the clinical picture: CRVO causes more diffuse visual impairment, requires an equally intensive injection regimen, and carries a higher risk of neovascular glaucoma, all of which weigh on day-to-day functioning.

The treatment burden itself is substantial for both types. Monthly or near-monthly clinic visits in the first year, the discomfort of repeated eye injections, and the uncertainty about whether vision will stabilize or relapse can generate real anxiety. Many patients also face parallel medical appointments with cardiologists or internists to address the systemic risk factors that contributed to the occlusion in the first place.

When a Vein Occlusion Uncovers Hidden Disease

One underappreciated aspect of retinal vein occlusion is its role as a sentinel event. Because the same vascular risk factors that cause a clot in the retina also drive heart attacks and strokes, an eye diagnosis can be the first clue that something systemic is wrong. Case reports describe BRVO as the presenting sign of previously undiagnosed hypertension, prompting referrals that uncovered additional conditions like chronic kidney disease.²⁵ Current screening protocols after a vein occlusion vary, but most retina specialists will check blood pressure, fasting blood sugar, cholesterol, and a complete blood count. For younger patients or those without obvious risk factors, a more detailed clotting workup is appropriate.

This interdisciplinary dimension is easy to overlook when the immediate concern is treating the eye. But managing the underlying systemic disease is what reduces the risk of a vein occlusion in the fellow eye and, more broadly, the risk of cardiovascular events elsewhere in the body. An ophthalmologist finding swollen retinal veins and a retinal internist finding high blood pressure are often looking at two faces of the same problem.